European Heart Journal · 2010 · 108 citations · 20 references
PharmacyPharmacokineticsPharmacologyCardiovascular PharmacotherapyClinical PharmacologyPharmacovigilanceAtherosclerosis PharmacotherapyCardiovascular DiseaseCardiovascular Drug SafetyCholesterol MetabolismCoronary Artery DiseaseLipid-lowering TherapyCholesterol Ester TransferHigh-density Lipoprotein Cholesterol ModulationLdl Cholesterol Lowering
AIMS: Co-primary objectives were to evaluate dalcetrapib (JTT-705/RO4607381), which targets cholesteryl ester transfer protein (CETP), effects on high-density lipoprotein cholesterol (HDL-C) in participants with coronary heart disease or risk equivalents and to evaluate potential changes in mesenteric lymph nodes. METHODS AND RESULTS: Double-blind trial with participants randomized (2:1) to dalcetrapib 900 mg/day (higher than 600 mg phase III dose) or placebo, both with atorvastatin, for 24 weeks (n = 135; one without post-baseline efficacy data was excluded from intent-to-treat population); a subset continued for 24-week extension (n = 77). Lipid changes and safety parameters were assessed. Mesenteric lymph nodes were evaluated by magnetic resonance imaging. Dalcetrapib increased HDL-C (33.4%, Week 24; 33.8%, Week 48), decreased CETP activity (-53.5%, Week 24; -56.5%, Week 48), and increased apolipoprotein A-I (11.4%, Week 24; 16.4%, Week 48). Dalcetrapib showed no clinically relevant differences vs. placebo in adverse events, laboratory parameters including aldosterone, electrocardiograms, and vital signs including blood pressure (BP). Dalcetrapib had no measurable, clinically relevant effect on lymph node size. CONCLUSION: Dalcetrapib 900 mg administered for up to 48 weeks showed no clinically relevant changes in lymph nodes, BP, or other safety parameters. Dalcetrapib effectively increased HDL-C over 48 weeks of treatment.
20
Effects of Torcetrapib in Patients at High Risk for Coronary Events
Philip J. Barter, Mark J. Caulfield, Mats Eriksson et al. · New England Journal of Medicine · 2007 · 3.1K citations · Full text
Medicine, Cardiology, Pharmacology +14
Effect of Torcetrapib on the Progression of Coronary Atherosclerosis
Steven E. Nissen, Jean‐Claude Tardif, Stephen J. Nicholls et al. · New England Journal of Medicine · 2007 · 965 citations · Full text
Medicine, Cardiology, Pharmacology +12
Relation of Gemfibrozil Treatment and Lipid Levels With Major Coronary Events
Sander J. Robins, Dorothea Collins, Janet Wittes et al. · JAMA · 2001 · 925 citations